The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ICML 2019 | MANTLE-FIRST results: outcomes in R/R younger MCL by therapy type

Name: MANTLE-FIRST results: outcomes in R/R younger MCL by therapy type
Uploaded: 2019-06-20T00:00:00.000Z
Duration: 2 min 10 s
Description: The results from the MANTLE-FIRST study are discussed here by Umberto Vitolo, MD, Città della Salute e della Scienza University Hospital, Turin, Italy, at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland. The outcomes of younger patients with relapsed/refractory mantle cell lymphoma (MCL) are explored.

Umberto Vitolo • 20 Jun 2019

ICML 2019

B-Cell Lymphoma Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Bendamustine Ibrutinib Rituximab

MANTLE-FIRST

The results from the MANTLE-FIRST study are discussed here by Umberto Vitolo, MD, Città della Salute e della Scienza University Hospital, Turin, Italy, at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland. The outcomes of younger patients with relapsed/refractory mantle cell lymphoma (MCL) are explored.